(2.07) Initial experience with Minimed 780G system in type 2 diabetic individuals at a tertiary diabetes centre in south India

Type 2 diabetes mellitus (T2DM) is a progressive disorder. With the increasing duration of T2DM, beta cell reserve is reduced and insulin is needed, often multiple daily doses. Although the MiniMed 780G Insulin Pump is approved for use in individuals with type 1 diabetes, we have been using it in T2DM with uncontrolled diabetes, who are on multiple daily injections as an off-label use of this pump. This paper deals with our initial experience with the Minimed 780 G system in T2DM.

Methods:

21 individuals with T2DM, who were initiated on MiniMed 780G Insulin Pump (Medtronics) at our centre, were enrolled in the study, after getting their informed consent. Data from the initial (baseline) and the last 30 days of follow-up was taken to look at the time in range (TIR), time below range (TBR), time above range (TAR) and glucose management indicator (GMI). Statistical analysis was done using SPSS software version 20.0.

Results:

The mean age at diagnosis of T2DM was 38.2 ± 10.1 years and the mean duration of diabetes was 22.6 ± 8.7 years. At baseline, HbA1c was 9.1 ± 1.6%, and fasting and stimulated C peptide levels were 0.4 ± 0.2 and 0.8 ± 0.4 pmol/L respectively.  After the pump use, there was an improvement in time in range (TIR: 70-180 mg/dl) from 65.2 to 71.0%, TAR reduced from 32.5 to 28.0%. The percentage of individuals with TIR >70% improved from 47.6% to 61.9, and GMI < 7% improved from 44.4% to 57.8% and the mean GMI at follow-up was 6.9%.  

Discussion/Conclusion:

This study shows that the MiniMed 780G Insulin Pump can be a useful tool in managing T2DM with uncontrolled blood glucose levels, despite multiple daily insulin dosages.